02 September 2010 - The new Illumina HiSeq 2000 is added to LGC Genomics’ next generation sequencing portfolio
LGC Genomics, the genomics division of LGC, announces the acquisition of the latest next generation sequencing technology Illumina HiSeq 2000 to its sequencing portfolio at its Berlin facilities.
The Illumina HiSeq 2000 sequencing platform - together with the Roche GS FLX Titanium and the high capacity Sanger sequencing ABI 3730xl technologies - will allow LGC Genomics to offer the whole range of next generation sequencing services. The sequencing platforms support various applications including de novo sequencing, re-sequencing, transcriptome and metagenome sequencing and they also extend the range of bioinformatic services on offer.
The Illumina HiSeq 2000 has the potential to generate up to 2 billion reads or 200 Gbp per run. It therefore improves the speed of large and complex sequencing projects and considerably reduces costs for the customers. The new next generation sequencing system will be integrated in the Berlin facility and several new positions for highly qualified scientists will be generated at LGC Genomics in Berlin.
John McQuillian – Managing Director of LGC Genomics Division commented: “Following the creation and rebranding of LGC Genomics as an independent division in April this year, adding the latest next generation sequencing technology to our portfolio is the next step on our path as LGC Genomics develops its operations to become Europe's leading genomics services provider.”
About LGC Genomics
LGC Genomics is a new division of the international science-based LGC Group and was established in April 2010 as part of a strategic reorganisation of LGC’s operational structure. LGC Genomics combines the strengths of the LGC Group’s former AGOWA genomics business – based in Berlin - with LGC’s ambitions for growth in the rapidly expanding international genomics market.
LGC Genomics delivers next generation sequencing services, DNA sequencing, genomic services, nucleic acid extraction services and DNA extraction products.
LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards (www.lgc.co.uk).LGC operates internationally through four divisions - LGC Forensics, LGC Genomics, LGC Standards and LGC Science & Technology. The LGC Group employs 1500 staff in 28 laboratories and centres across Europe as well as in India and China.
About LGC
LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards. A progressive and innovative enterprise, LGC operates in socially responsible fields underpinning the safety, health and security of the public and the regulation of industry, for UK government departments and blue chip clients.
LGC operates internationally through four divisions - LGC Forensics, LGC Genomics, LGC Standards and LGC Science & Technology, which includes specialist laboratories delivering contracts for the Department for Business, Innovation and Skills (BIS) and supporting LGC's designated role as the UK's National Measurement Institute for chemical and bioanalytical measurement.
Our operations are extensively accredited to international quality standards such as ISO 17025. With headquarters in Teddington, South West London, the LGC Group employs 1500 staff in 28 laboratories and centres across Europe and at sites in India, China and the US. Privatised in 1996 and now majority-owned by funds managed by Bridgepoint, LGC was founded almost 170 years ago as the Laboratory of the Government Chemist - a statutory function maintained by LGC today.
Franziska Sommerfeld
Marketing / PR Coordinator
LGC Genomics GmbH
Ostendstr. 25 • TGS Haus 8
12459 Berlin • Germany
Tel: +49 (0)30 5304 2204 • Fax: +49 (0)30 5304 2201
Email: franziska.sommerfeld@lgcgenomics.com • Web: www.lgcgenomics.com
Amtsgericht Berlin Charlottenburg • HRB 48332
Geschäftsführer: Dr. Steffen Krüger, Uwe de Buhr